A clinical-phase cancer biotech with nanomedicine partnering opportunities

Harnessing its unique CriPec technology, Cristal Therapeutics is improving the treatment options for patients with a range of solid tumors by creating transiently stable nanomedicines.

Like Comment
Page of
Go to the profile of Cristal Therapeutics

Cristal Therapeutics

Cristal Therapeutics is a clinical stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need and considerable commercial potential. The Company’s product candidates are based on its proprietary CriPec® polymeric nanoparticle technology platform, which enables the design of customised nanomedicines with superior therapeutic profiles. CriPec®-based products have the potential to provide enhanced efficacy and reduced side effect profiles, thus offering improved disease treatment. The Company’s lead product, CPC634, is in clinical Phase 2 studies for the treatment of solid tumours. The Company has several other products in preclinical development focussed on the treatment of cancer. Cristal Therapeutics has a number of partnerships with large pharma and mature biotech companies. Cristal Therapeutics is a private company that has raised over € 20M to date. The Company’s headquarters and laboratories are located in Maastricht, The Netherlands.

No comments yet.